270P - Prognostic value of residual disease in breast and nodes (RDBN), a histopathologic system to evaluate the response after neoadjuvant chemotherapy (...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Early Stage
Pathology/Molecular Biology
Presenter Vanesa Pons
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors V. Pons1, J.A. Pérez-Fidalgo1, O. Burgués2, M.T. Martinez1, P. Martín1, B. Bermejo1, J.M. Cejalvo1, K. Pinilla1, A. Lluch-Hernandez1
  • 1Medical Oncology And Hematology Unit, Health Research Institute INCLIVA, 46010 - Valencia/ES
  • 2Pathology, HOSPITAL CLÍNICO UNIVERSITARIO VALENCIA, 46010 - VALENCIA/ES

Abstract

Aim

Many studies have shown the prognostic value of the complete pathological response after NAC in breast cancer. There are many histopathological classification systems but the most frecuently used are Miller-Payne and Residual Cancer Burden (RCB). The aim of this study is to validate a new one, Residual Disease in Breast and Nodes (RDBN).

Methods

In this retrospective study 318 patients treated in our institution between January 2005 and October 2012 with NAC were enrolled. 86,7% of the patients received an anthracycline and taxane based chemotherapy, asociated with trastuzumab in patients with overexpression/amplification of Her2. All patients with estrogen and/or progesterone receptor expression received endocrine therapy. For all of them RDBN was calculated taking into account tumour size, axillary lymph node involvement and histologic grade (HG). A correlation with survival was done using the Kaplan-Meier method and Cox regression model.

Results

From the 318 patients included in this study, 8,2% had stage I tumours at diagnosis, 71,4% stage II and 20,4% stage III. 80,5% of the patients presented positivity for hormonal receptors and 31% for Her2. After the treatment, 14,77% had RDBN-I (pathological complete response), 37,11% RDBN-II, 30,18% RDBN-III and 17,92% RDBN-IV. Patients with RDBN-I had more frequently HG-III tumours without hormonal receptors expression. By contrast, RDBN-II to IV were associated to HG-II, positive hormonal receptors and no Her2 overexpression/amplification. Overall survival (OS) was 100% for RDBN-I, 99,4% for RDBN-II, 91,7% for RDBN-III and 71,9% for RDBN-IV, p < 0.001. Disease-free survival (DFS) was 91,5% for RDBN I-II patients, 82,3% for RDBN-III and 38,6% for RDBN-IV, p< 0.001.

Conclusions

RDBN is statistically asociated with OS and DFS.

Disclosure

All authors have declared no conflicts of interest.